Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price traded up 7.9% during mid-day trading on Thursday . The stock traded as high as $69.36 and last traded at $68.29, with a volume of 665,216 shares changing hands. The stock had previously closed at $63.28.

Several equities analysts have issued reports on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Sunday, July 17th. Canaccord Genuity reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. Cowen and Company reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday. Finally, Leerink Swann reaffirmed a “buy” rating and set a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Three investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $100.41.

The stock has a 50 day moving average of $55.61 and a 200-day moving average of $61.50. The stock’s market capitalization is $2.66 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.02. During the same period last year, the business earned ($0.83) EPS. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.89) EPS for the current year.

In other news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $50.85, for a total transaction of $1,017,000.00. Following the transaction, the chief executive officer now directly owns 513,597 shares of the company’s stock, valued at approximately $26,116,407.45. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Sunil Agarwal sold 649 shares of the company’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total transaction of $34,189.32. The disclosure for this sale can be found here.

Other institutional investors recently bought and sold shares of the company. Trexquant Investment LP bought a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $1,010,000. GSA Capital Partners LLP boosted its position in Ultragenyx Pharmaceutical by 12.2% in the fourth quarter. GSA Capital Partners LLP now owns 11,188 shares of the biopharmaceutical company’s stock worth $1,255,000 after buying an additional 1,218 shares during the period. California Public Employees Retirement System boosted its position in Ultragenyx Pharmaceutical by 7.6% in the fourth quarter. California Public Employees Retirement System now owns 55,300 shares of the biopharmaceutical company’s stock worth $6,204,000 after buying an additional 3,900 shares during the period. Dimensional Fund Advisors LP boosted its position in Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock worth $6,414,000 after buying an additional 5,139 shares during the period. Finally, Jennison Associates LLC boosted its position in Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock worth $84,739,000 after buying an additional 109,724 shares during the period.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.